What is the price target for ALDX stock?
12 analysts have analysed ALDX and the average price target is 9.86 USD. This implies a price increase of 444.75% is expected in the next year compared to the current price of 1.81.
ALDEYRA THERAPEUTICS INC (ALDX) Forecast, Price Target & Analyst Ratings
NASDAQ:ALDX • US01438T1060
Current stock price
1.81 USD
-0.02 (-1.09%)
At close:
1.85 USD
+0.04 (+2.21%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALDEYRA THERAPEUTICS INC (ALDX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.09
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.86
Upside
+ 444.75%
From current price of $1.81 to mean target of $9.86, Based on 12 analyst forecasts
Low
$7.07
Median
$9.69
High
$13.65
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for ALDX. The average price target is 9.86 USD. This implies a price increase of 444.75% is expected in the next year compared to the current price of 1.81.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
ALDX was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about ALDX.
In the previous month the buy percentage consensus was at a similar level.
ALDX was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-11-10 | BTIG | Reiterate | Buy -> Buy |
| 2025-05-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-07 | BTIG | Maintains | Buy -> Buy |
| 2025-04-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-06 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2024-04-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-17 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2023-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-06-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-01 | Citigroup | Maintains | Buy -> Buy |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-06-09 | Citigroup | Maintains | Buy |
| 2021-12-21 | SVB Leerink | Maintains | Outperform |
| 2021-12-21 | Citigroup | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.09
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 46.00%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
-2.44%
Next Earnings Summary
ALDX is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.09 USD and the consensus revenue estimate is 0 USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 50.89% | N/A 123.43% | N/A | N/A 64.65% | N/A 21.49% | N/A -14.09% | N/A -2.39% | |||||||||||
| EBITDA YoY % growth | -11.97M | -18.66M -55.89% | -22.45M -20.31% | -39.63M -76.53% | -56.4M -42.32% | -34.61M 38.63% | -55.96M -61.69% | -62.42M -11.54% | -42.531M 31.86% | -59.867M -40.76% | N/A 8.33% | N/A 72.06% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.99M | -18.7M -55.96% | -22.49M -20.27% | -39.7M -76.52% | -56.5M -42.32% | -34.67M 38.64% | -56.22M -62.16% | -62.68M -11.49% | -42.794M 31.73% | -60.117M -40.48% | N/A 69.79% | N/A -83.50% | N/A 157.80% | N/A 161.39% | N/A 56.99% | N/A 19.62% | N/A 16.84% | N/A -7.66% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -1.40 | -1.67 -19.29% | -1.40 16.17% | -1.90 -35.71% | -2.23 -17.37% | -1.12 49.78% | -1.07 4.36% | -1.06 1.04% | -0.64 39.62% | -0.94 -46.88% | -0.56 40.43% | N/A 9.84% | N/A 132.32% | N/A 310.42% | N/A 215.99% | N/A 27.47% | N/A -54.63% | N/A -2.50% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 46.00% | -0.15 4.38% | -0.13 -2.00% | -0.12 -22.40% |
| Revenue Q2Q % growth | 5.1M | 12.813M | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -9.471M 9.18% | -9.776M 3.86% | -5.503M 31.22% | 1.107M -90.42% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
47.30%
EPS Next 5 Year
46.80%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
49.95%
Revenue Next 5 Year
46.48%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ALDEYRA THERAPEUTICS INC / ALDX Forecast FAQ
When does ALDEYRA THERAPEUTICS INC (ALDX) report earnings?
ALDEYRA THERAPEUTICS INC (ALDX) will report earnings on 2026-05-12.
What are the consensus estimates for ALDX stock next earnings?
The consensus EPS estimate for the next earnings of ALDEYRA THERAPEUTICS INC (ALDX) is -0.09 USD and the consensus revenue estimate is 0 USD.
Can you provide the expected long term growth rate for ALDEYRA THERAPEUTICS INC stock?
The expected long term growth rate for ALDEYRA THERAPEUTICS INC (ALDX) is 49.95%.